MX2009003160A - Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico. - Google Patents

Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico.

Info

Publication number
MX2009003160A
MX2009003160A MX2009003160A MX2009003160A MX2009003160A MX 2009003160 A MX2009003160 A MX 2009003160A MX 2009003160 A MX2009003160 A MX 2009003160A MX 2009003160 A MX2009003160 A MX 2009003160A MX 2009003160 A MX2009003160 A MX 2009003160A
Authority
MX
Mexico
Prior art keywords
crystalline forms
oxadiazol
benzoic acid
fhjorophenyl
methods
Prior art date
Application number
MX2009003160A
Other languages
English (en)
Inventor
Young-Choon Moon
Neil G Almstead
Peter Seongwoo Hwang
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2009003160A publication Critical patent/MX2009003160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Abstract

La presente invención se relaciona a formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico, (fórmula (I)), composiciones farmacéuticas y formas de dosis que comprenden las formas cristalinas, métodos para crear las formas cristalinas y métodos para su usos para el tratamiento, prevención o manejo de enfermedades mejoradas por la modulación de la terminación prematura de la traducción o la degradación de ARNm mediada por mutaciones terminadoras.
MX2009003160A 2006-09-25 2007-09-24 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico. MX2009003160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84732606P 2006-09-25 2006-09-25
PCT/US2007/020633 WO2008039431A2 (en) 2006-09-25 2007-09-24 Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

Publications (1)

Publication Number Publication Date
MX2009003160A true MX2009003160A (es) 2009-04-06

Family

ID=39123850

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011007120A MX344418B (es) 2006-09-25 2007-09-24 Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
MX2009003160A MX2009003160A (es) 2006-09-25 2007-09-24 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011007120A MX344418B (es) 2006-09-25 2007-09-24 Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.

Country Status (29)

Country Link
US (10) US7863456B2 (es)
EP (2) EP2076501B8 (es)
JP (6) JP5714228B2 (es)
KR (1) KR101430144B1 (es)
CN (3) CN104341371A (es)
AR (2) AR062963A1 (es)
AU (1) AU2007300542B2 (es)
BR (1) BRPI0717107A2 (es)
CA (1) CA2663574C (es)
CL (1) CL2007002743A1 (es)
DK (1) DK2076501T3 (es)
ES (2) ES2563958T3 (es)
HK (1) HK1207070A1 (es)
HU (1) HUE028503T2 (es)
IL (1) IL197717A (es)
LT (1) LTC2076501I2 (es)
MX (2) MX344418B (es)
MY (1) MY191209A (es)
NO (1) NO341858B1 (es)
NZ (1) NZ575795A (es)
PE (3) PE20081225A1 (es)
PL (2) PL2076501T3 (es)
PT (1) PT2076501E (es)
SG (2) SG10201609581TA (es)
SI (1) SI2076501T1 (es)
TW (2) TWI452038B (es)
UA (1) UA99600C2 (es)
WO (1) WO2008039431A2 (es)
ZA (1) ZA200901949B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
MX2007012206A (es) * 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
MX2008012515A (es) * 2006-03-30 2008-11-19 Ptc Therapeutics Inc Metodos para la produccion de proteina funcional a partir de adn que tiene una mutacion sin sentido y el tratamiento de trastornos asociados con la misma.
MX344418B (es) 2006-09-25 2016-12-15 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
KR20090074231A (ko) 2006-10-12 2009-07-06 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
CN104710385B (zh) 2010-03-12 2018-11-09 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
EP2981597A1 (en) 2013-04-03 2016-02-10 GFO Oil LLC Methods and systems for generating aldehydes from organic seed oils
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
MY196130A (en) 2015-03-10 2023-03-16 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
CA3003132A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
WO2018050706A1 (en) * 2016-09-13 2018-03-22 Marco Cipolli Method of treatment of shwachman-diamond syndrome
WO2019061324A1 (en) * 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
KR20200068659A (ko) 2017-10-11 2020-06-15 오리진 디스커버리 테크놀로지스 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
JP7339900B2 (ja) * 2020-02-26 2023-09-06 新 井上 視野異常診断方法、視野異常診断装置
WO2023121199A1 (ko) * 2021-12-21 2023-06-29 재단법인 아산사회복지재단 신경섬유종증의 치료적 및 진단적 타겟으로서의 활성화된 ras 및 그의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004001010A2 (en) * 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US6889231B1 (en) * 2002-08-01 2005-05-03 Oracle International Corporation Asynchronous information sharing system
EP1536790A2 (en) * 2002-08-09 2005-06-08 AstraZeneca AB Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
WO2004110351A2 (en) * 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
EP1812071A2 (en) * 2004-10-13 2007-08-01 PTC Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
JP2008523090A (ja) * 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
MX2007012206A (es) 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
PL2059513T3 (pl) 2006-09-08 2013-06-28 Ptc Therapeutics Inc Sposób wytwarzania pochodnych 1,2,4-oksadiazolowych kwasu benzoesowego
MX344418B (es) * 2006-09-25 2016-12-15 Ptc Therapeutics Inc Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
KR102497273B1 (ko) * 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염

Also Published As

Publication number Publication date
US20220023268A1 (en) 2022-01-27
US20080171377A1 (en) 2008-07-17
US20160193189A1 (en) 2016-07-07
SI2076501T1 (sl) 2016-05-31
US20130158081A1 (en) 2013-06-20
JP5714228B2 (ja) 2015-05-07
SG185979A1 (en) 2012-12-28
EP2559689A1 (en) 2013-02-20
CA2663574A1 (en) 2008-04-03
US20110040100A1 (en) 2011-02-17
WO2008039431A2 (en) 2008-04-03
PL2076501T3 (pl) 2016-06-30
CN104341371A (zh) 2015-02-11
HK1207070A1 (en) 2016-01-22
RU2474577C2 (ru) 2013-02-10
TW201420578A (zh) 2014-06-01
ZA200901949B (en) 2010-07-28
SG10201609581TA (en) 2016-12-29
AR062963A1 (es) 2008-12-17
US20210330647A1 (en) 2021-10-28
LTC2076501I2 (lt) 2017-10-10
ES2655338T3 (es) 2018-02-19
EP2076501B8 (en) 2019-11-13
JP2021130697A (ja) 2021-09-09
TW200823181A (en) 2008-06-01
US7863456B2 (en) 2011-01-04
US8748625B2 (en) 2014-06-10
JP2017160253A (ja) 2017-09-14
US20200330440A1 (en) 2020-10-22
US8394966B2 (en) 2013-03-12
AU2007300542B2 (en) 2012-05-17
US10028939B2 (en) 2018-07-24
JP2023078271A (ja) 2023-06-06
CL2007002743A1 (es) 2008-07-11
JP7245868B2 (ja) 2023-03-24
NZ575795A (en) 2012-03-30
CN101541770A (zh) 2009-09-23
JP2019104752A (ja) 2019-06-27
EP2076501A2 (en) 2009-07-08
MX344418B (es) 2016-12-15
CN102382075B (zh) 2015-10-28
BRPI0717107A2 (pt) 2013-10-15
JP6407733B2 (ja) 2018-10-17
US20190231754A1 (en) 2019-08-01
CN102382075A (zh) 2012-03-21
MY191209A (en) 2022-06-08
PT2076501E (pt) 2016-03-31
JP2015110607A (ja) 2015-06-18
WO2008039431B1 (en) 2008-07-10
TWI452038B (zh) 2014-09-11
RU2009115649A (ru) 2010-11-10
PE20151445A1 (es) 2015-09-28
JP2010504340A (ja) 2010-02-12
IL197717A0 (en) 2009-12-24
HUE028503T2 (en) 2016-12-28
KR101430144B1 (ko) 2014-08-13
US10959988B2 (en) 2021-03-30
NO20091488L (no) 2009-06-17
PL2559689T3 (pl) 2018-04-30
US20140235679A1 (en) 2014-08-21
US9309206B2 (en) 2016-04-12
DK2076501T3 (da) 2016-02-29
JP6495375B2 (ja) 2019-04-03
WO2008039431A3 (en) 2008-05-08
TWI496775B (zh) 2015-08-21
US20180296538A1 (en) 2018-10-18
NO341858B1 (no) 2018-02-12
CA2663574C (en) 2015-11-24
US10300047B2 (en) 2019-05-28
ES2563958T3 (es) 2016-03-16
EP2559689B1 (en) 2017-11-29
AR109300A2 (es) 2018-11-14
UA99600C2 (en) 2012-09-10
PE20120768A1 (es) 2012-06-27
PE20081225A1 (es) 2008-09-04
KR20090057457A (ko) 2009-06-05
IL197717A (en) 2015-06-30
EP2076501B1 (en) 2015-12-02
AU2007300542A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
MX344418B (es) Formas cristalinas del acido 3-[5- 2- fluorofenil)- [1,2,4] oxadiazol-3-il]- benzoico.
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MY149143A (en) Thiazole compounds as protien kinase b (pkb) inhibitors
WO2011056985A3 (en) Substituted heterocyclic compounds
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
GEP20125565B (en) Lactam compounds and their pharmaceutical use
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
SI2150530T1 (sl) Substituirani sulfonamidni derivati
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
HK1136827A1 (en) Spirocyclic cyclohexane derivatives
GEP20135806B (en) Lactams as beta secretase inhibitors
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
ZA200704913B (en) 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
NZ710574A (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
MY163501A (en) Anti-biofilm carbonate compouns for use in oral care compositions
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
DE602005014629D1 (de) Pyrazolphenylderivate als ppar-aktivatoren

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration